Portal de investigação
CAR-Ts: new perspectives in cancer therapy
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Abrantes, R
- Duarte, HO
- Gomes, C
- Wälchli, S
Abstract
Chimeric antigen receptor (CAR)-T-cell therapy is a promising anticancer treatment that exploits the host's immune system to fight cancer. CAR-T cell therapy relies on immune cells being modified to express an artificial receptor targeting cancer-specific markers, and infused into the patients where they will recognize and eliminate the tumour. Although CAR-T cell therapy has produced encouraging outcomes in patients with haematologic malignancies, solid tumours remain challenging to treat, mainly due to the lack of cancer-specific molecular targets and the hostile, often immunosuppressive, tumour microenvironment. CAR-T cell therapy also depends on the quality of the injected product, which is closely connected to CAR design. Here, we explain the technology of CAR-Ts, focusing on the composition of CARs, their application, and limitations in cancer therapy, as well as on the current strategies to overcome the challenges encountered. We also address potential future targets to overcome the flaws of CAR-T cell technology in the treatment of cancer, emphasizing glycan antigens, the aberrant forms of which attain high tumour-specific expression, as promising targets for CAR-T cell therapy.
Dados da publicação
- ISSN/ISSNe:
- 0014-5793, 1873-3468
- Tipo:
- Review
- Páginas:
- 403-416
FEBS Letters Wiley-Blackwell
Citações Recebidas na Web of Science: 13
Documentos
- Não há documentos
Filiações
Keywords
- cancer; CAR-T; cell therapy; chimeric antigen receptor; glycans; glycosylation; tumour therapy
Financiamento
Proyectos asociados
Expression of Thomsen-Friedenreich Antigen in colorectal cancer and association with microsatellite instability
Investigador Principal: Celso Albuquerque Reis
Estudo Clínico Académico . 2021
Citar a publicação
Abrantes R,Duarte HO,Gomes C,Wälchli S,Reis CA. CAR-Ts: new perspectives in cancer therapy. FEBS Lett. 2022. 596(4):p. 403-416. IF:3,500. (2).
